- Both ketamine and psilocin microdosing caused mild anxiety in rats, indicated by reduced exploratory behavior on an elevated open surface.
- Lower doses of both substances produced comparable effects, suggesting a potential common neurotransmitter/receptor mechanism governing their actions.
- Results imply that therapeutic microdosing with these substances may be counterproductive in managing anxiety, necessitating further research for clinical application.
Introduction to Study
The researchers aimed to investigate the potential lasting effects of ketamine and psilocin microdosing on anxiety-related behaviors in rats, addressing the growing interest in microdosing as an alternative treatment for anxiety. Despite anecdotal reports suggesting benefits from this practice, there has been a lack of rigorous scientific research supporting these claims.
Methods
A total of 40 Wistar rats were used, which were divided into groups to receive either ketamine, psilocin, or a saline control over six days. The specific doses were 0.5 or 3 mg/kg for ketamine and 0.05 or 0.075 mg/kg for psilocin. Behavioral assessments were conducted through the elevated plus-maze test, whereby the animals’ entries and time spent in open versus closed arms were measured to gauge anxiety levels. Following drug administration, statistical analysis determined the significance of the results through one-way ANOVA and subsequent t-tests.
Results of the Study
The findings suggested that both substances exhibited a mildly anxious profile. For ketamine, the lower dose led to a notable reduction in entries into open arms of the maze, while psilocin displayed a comparable reduction at 0.05 mg/kg. Altogether, their effects suggested an increase in anxiety-like behaviors after treatment, hinting at a potential anxiogenic action that may counter the desired therapeutic effect.
Discussion
The researchers concluded that microdosing ketamine and psilocin elicited behavioral changes consistent with increased anxiety, challenging the notion that such practices are beneficial for treating anxiety disorders. The results highlighted shared pharmacological properties between ketamine and psilocin that likely stem from common pathways, such as the activation of 5-HT2A receptors, which are implicated in mood regulation. Despite the initial anxiety-inducing effects observed, further exploration is necessary to fully understand the implications for clinical use and to determine if these outcomes replicate in diverse models of anxiety and other psychological conditions.
Conclusion
While intermittent microdosing with ketamine and psilocin undoubtedly affects anxiety-related behavior, the overall impact is modest and potentially counterproductive. The study underscores the significance of conducting further research with various conditions to ascertain definitive therapeutic roles for these substances in treating anxiety and other mental health-related issues.
Read the full paper summary on Blossom.
